
    
      A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of
      Rezafungin for injection versus the standard antimicrobial regimen for the prevention of
      invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation.
    
  